1 / 13

Translating Biomarker Discovery to Clinical Application

Translating Biomarker Discovery to Clinical Application. Sudhir Srivastava, Ph.D., M.P.H. Cancer Biomarkers Research Group. GOALS. Discover, develop and validate biomarkers for cancer detection, diagnosis and risk assessment

fiorello
Télécharger la présentation

Translating Biomarker Discovery to Clinical Application

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Translating Biomarker Discovery to Clinical Application Sudhir Srivastava, Ph.D., M.P.H. Cancer Biomarkers Research Group

  2. GOALS • Discover, develop and validate biomarkers for cancer detection, diagnosis and risk assessment • Conduct correlative studies/trials to validate biomarkers as indicators of early cancer, pre-invasive cancer, risk, or as surrogate endpoints • Develop quality assurance programs for biomarker testing and evaluation • Forge public-private partnerships

  3. INVESTIGATOR-DRIVEN CONSORTIUM An “infrastructure” for supporting collaborative research on molecular, genetic and other biomarkers in human cancer detection and risk assessment.

  4. MANAGEMENT STRUCTURE Prostate & Other Urologic Cancers Breast & Ob/Gyn Cancers Prioritization Technology Sharing Collaboration Communication and Workshop Data sharing and Informatics Steering Committee Executive Committee Colon and Other GI Cancers Policy Making Subcommittees Lung and Upper Respiratory Cancers

  5. ORGANIZATIONAL SUCCESS:A Catalyst for Innovations and Partnership • EDRN Business Model and Project Management Reviewed and Cited by Many Scientific Journals and Working Groups for Best Practices: • Informatics to Manage and Support Biomarker Research (NCI-FDA-AACR Biomarker Collaborative Working Group Reports, Institute of Medicine on Biomarker) • Conducting Discovery and Validation Research (JNCI, J. Proteome Research) • Collaborative Model for Biomarker Research (Nature) • Milestones-driven Project Management that Ensure Timely Completion • NCI Translational Research Working Group The EDRN structure has been cited by the National Academy of Sciences Institute of Medicine as an effective team-based organization (Large Scale Biomedical Science, Institute of Medicine 2001); and for following best practices in Biospecimen Resources for the Genomic and Proteomic Era (Rand Science and Technology Publication, 2003), and Cancer Informatics (Eds. Silva, Ball, Chute, et. al., 2002 and in Cancer Biomarkers, Institute of Medicine 2007). Continues…

  6. ORGANIZATIONAL SUCCESS:A Catalyst for Innovations and Partnership Continued. • Rewards Collaboration and Promotes Team Science (EDRN Investigator received the first-ever AACR Team Science Award: Arul Chinnaiyan). • EDRN is as an Unexpected Catalyst for Innovation, Partnerships, and Biomarker Research Know-How (An EDRN investigator received a DOD Innovator Award on research ideas supported by EDRN). • Diagnostic firms, large or small, are seeking partnerships with EDRN.

  7. ORGANIZATIONAL SUCCESS:A Model System for Translational Research • An integrated, collaborative model that: • Uses a novel mechanism to reward collaboration and promotes inclusiveness through its Associate Membership Program. • Has developed a roadmap for biomarkers discovery and validation . • Has helped developed biomarker metrology to develop, design and deliver biomarker research free of chance, bias and over-fitting (Pepe et.al., Ransohoff). • Has championed protocol-driven, phase-approach to proteomics evaluation for cancer diagnostic. • Disseminates resources for extramural communities on protocols, reagents, reference sets, study designs and statistical methodologies.

  8. PHASES OF BIOMARKER VALIDATION Source: J. Natl. Cancer Inst. 93, 1054-1061, 2001

  9. EDRN PROGRAM FOR RAPID INDEPENDENTDIAGNOSTIC EVALUATION (PRIDE) • A RAID-like mechanism that: • Encourages extramural investigators to seek assistance from EDRN in cross-laboratory validation of their biomarker assays. • Helps develop and institutes quality assurance programs for biomarker testing and evaluation. • PRIDE announcement is published in NIH Guide yearly.

  10. PRESENT AND FUTURE • EDRN already practices management philosophy • promoted by TRWG. • TRWG- supported Risk Device Pathways are already • being supported by EDRN. • The Network’s productivity, funding opportunities and • infrastructure have fashioned a new environment for • biomarker research. • A number of biomarker tests will be ready for submission • to FDA, a remarkable achievement considering the history • of approval of diagnostic markers by FDA.

  11. FDA APPROVAL OF CANCER BIOMARKERS Joseph A. Ludwig*‡ and John N. Weinstein* Nature Rev. Cancer 2005

  12. SIGNIFICANT NOTES • EDRN 4th Report Released January 2008 • EDRN 5th Annual Workshop March 16-19, Bethesda, MD • AACR Sunrise Session on EDRN April 15, 2008

  13. UPDATES • BIOMARKER DISCOVERY: Dr. Sam Hanash • BIOMARKER VALIDATION: Dr. Ian Thompson • BIOMARKER REFERENCE LABORATORIES: Dr. Dan Chan • STATISTICAL AND INFORMATICS: Drs. Ziding Feng, Mark Thornquist, and Dan Crichton

More Related